Muscle sympathetic nerve activity in COPD: a systematic review and meta-analysis
Source: PubMed Central Open Access, NCBI / U.S. National Library of Medicine
Background Cardiovascular disease is a primary driver of mortality in COPD. Elevated sympathetic nerve activity is a key proposed mechanism, but the magnitude of this autonomic overactivity has not been quantified in a pooled analysis. Objective To determine if adults with COPD exhibit higher resting muscle sympathetic nerve activity (MSNA) than healthy controls, assess associated cardiorespiratory effects, and evaluate the short-term impact of COPD interventions on MSNA. Methods Following the Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines, eight databases were searched from inception to 15 May 2025 to inform this systematic review and meta-analysis (PROSPERO CRD420251044931). Eligible studies included adults with spirometry-defined COPD in whom MSNA was measured by microneurography at rest. Primary outcomes were MSNA burst frequency (bursts·min) and incidence (bursts per 100 heartbeats). Secondary outcomes included resting heart rate and blood pressure. Results A total of 11 studies (171 COPD participants, 105 controls) met inclusion criteria. Compared with controls, COPD was associated with markedly higher MSNA, burst frequency (+18.5, 95% CI 9.4–27.7 bursts·min) and burst incidence (+21.3, 95% CI 9.2–33.4 bursts per 100 heartbeats). Resting heart rate was also elevated (+10.7, 95% CI 6.1–15.3 beats·min), while blood pressure did not differ significantly. Three studies on noninvasive ventilation or inhaled β-agonists found no significant poole
Abstract
Background Cardiovascular disease is a primary driver of mortality in COPD. Elevated sympathetic nerve activity is a key proposed mechanism, but the magnitude of this autonomic overactivity has not been quantified in a pooled analysis. Objective To determine if adults with COPD exhibit higher resting muscle sympathetic nerve activity (MSNA) than healthy controls, assess associated cardiorespiratory effects, and evaluate the short-term impact of COPD interventions on MSNA. Methods Following the Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines, eight databases were searched from inception to 15 May 2025 to inform this systematic review and meta-analysis (PROSPERO CRD420251044931). Eligible studies included adults with spirometry-defined COPD in whom MSNA was measured by microneurography at rest. Primary outcomes were MSNA burst frequency (bursts·min) and incidence (bursts per 100 heartbeats). Secondary outcomes included resting heart rate and blood pressure. Results A total of 11 studies (171 COPD participants, 105 controls) met inclusion criteria. Compared with controls, COPD was associated with markedly higher MSNA, burst frequency (+18.5, 95% CI 9.4–27.7 bursts·min) and burst incidence (+21.3, 95% CI 9.2–33.4 bursts per 100 heartbeats). Resting heart rate was also elevated (+10.7, 95% CI 6.1–15.3 beats·min), while blood pressure did not differ significantly. Three studies on noninvasive ventilation or inhaled β-agonists found no significant pooled changes in MSNA. Conclusions Resting MSNA is significantly elevated in patients with COPD despite normal blood pressure. This chronic sympathetic excitation likely contributes to COPD-related cardiovascular morbidity and exercise intolerance, highlighting the importance of developing therapies that reduce sympathetic nerve activity. Shareable abstract https://bit.ly/40H645f short abstract-1